Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CTNM 
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: CTNM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.18
1 Year Target Price $22.18
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 48.72% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 322.17M USD | Price to earnings Ratio - | 1Y Target Price 22.18 |
Price to earnings Ratio - | 1Y Target Price 22.18 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 3.35 - 15.25 | Updated Date 12/8/2025 |
52 Weeks Range 3.35 - 15.25 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.89% | Return on Equity (TTM) -30.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 145260920 | Price to Sales(TTM) 11.15 |
Enterprise Value 145260920 | Price to Sales(TTM) 11.15 | ||
Enterprise Value to Revenue 8.25 | Enterprise Value to EBITDA 20.76 | Shares Outstanding 23099173 | Shares Floating 16678097 |
Shares Outstanding 23099173 | Shares Floating 16678097 | ||
Percent Insiders 1.51 | Percent Institutions 76.9 |
Upturn AI SWOT
Contineum Therapeutics, Inc. Class A Common Stock
Company Overview
History and Background
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. Founded in 2020, the company has rapidly advanced its lead candidate, CON086, into clinical trials. Significant milestones include the initiation of Phase 1 studies for CON086.
Core Business Areas
- Inflammatory and Fibrotic Diseases: Contineum Therapeutics is dedicated to discovering and developing small molecule therapies targeting underlying mechanisms of chronic inflammatory and fibrotic diseases, aiming to address unmet medical needs in conditions such as idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions.
Leadership and Structure
Contineum Therapeutics is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The exact organizational structure is typical for a clinical-stage biotech, with departments focused on research and development, clinical operations, regulatory affairs, and business development. Specific leadership roles are usually detailed in company filings like SEC Form S-1 or annual reports.
Top Products and Market Share
Key Offerings
- CON086: CON086 is Contineum Therapeutics' lead drug candidate, a novel small molecule inhibitor of the Syk tyrosine kinase. It is being developed for the treatment of fibrotic interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Current market share data is not applicable as the product is in early-stage clinical development. Key competitors in the IPF space include companies developing antifibrotic drugs like pirfenidone and nintedanib.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on rare and chronic diseases like fibrotic interstitial lung diseases, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. It is also a highly competitive landscape with a strong emphasis on innovation and the development of targeted therapies.
Positioning
Contineum Therapeutics positions itself as an innovator in the fibrotic disease space with a differentiated mechanism of action. Its focus on Syk inhibition aims to offer a potentially more effective or safer alternative to existing treatments. The company's success will depend on demonstrating robust clinical efficacy and safety data for CON086.
Total Addressable Market (TAM)
The total addressable market for fibrotic interstitial lung diseases, particularly IPF, is substantial and growing due to an aging population and increased disease awareness. While specific TAM figures vary by source and definition, it represents a multi-billion dollar global market. Contineum Therapeutics aims to capture a significant portion of this market with a differentiated therapeutic offering if CON086 proves successful in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (CON086) with a well-defined mechanism of action.
- Experienced management team with expertise in drug development.
- Focus on a significant unmet medical need in fibrotic diseases.
- Adequate funding to advance lead candidate through early clinical trials.
Weaknesses
- Clinical-stage company with no approved products, thus no revenue generation.
- High reliance on the success of a single lead candidate.
- Limited financial resources compared to larger pharmaceutical companies.
- Execution risk associated with clinical trial design and patient recruitment.
Opportunities
- Potential to address a significant unmet need in fibrotic diseases.
- Partnership or acquisition opportunities with larger pharmaceutical companies.
- Expansion of CON086 to other fibrotic indications.
- Advancements in understanding fibrotic disease pathways.
Threats
- Clinical trial failures or adverse events.
- Competition from existing and emerging therapies.
- Regulatory hurdles and delays in drug approval.
- Challenges in securing long-term financing.
- Intellectual property challenges.
Competitors and Market Share
Key Competitors
- Promedior Inc. (Private)
- Galapagos NV (GLPG)
- FibroGen, Inc. (FGEN)
- Roche Holding AG (RHHBY)
Competitive Landscape
Contineum Therapeutics competes in the highly competitive pharmaceutical landscape for fibrotic diseases. Its advantages lie in its focused approach on a novel mechanism of action (Syk inhibition) and its potential to address unmet needs. However, it faces significant disadvantages in terms of established market presence, larger R&D budgets, and existing approved therapies held by larger competitors.
Growth Trajectory and Initiatives
Historical Growth: As a relatively new company, Contineum Therapeutics' historical growth has been characterized by its establishment, securing initial funding, and advancing its lead drug candidate into clinical development. The focus has been on building the scientific and operational infrastructure necessary for drug discovery and development.
Future Projections: Future projections for Contineum Therapeutics are highly dependent on the clinical success and regulatory approval of CON086. Analyst estimates, if available, would likely focus on potential peak sales figures for CON086 in its target indications and the potential for future pipeline expansion. However, at this stage, specific projections are speculative.
Recent Initiatives: Recent initiatives likely include the initiation and progression of clinical trials for CON086, building out the scientific team, and ongoing efforts to secure necessary financing to support its development pipeline.
Summary
Contineum Therapeutics is a promising clinical-stage biopharmaceutical company with a novel approach to treating fibrotic diseases. Its lead candidate, CON086, targets a significant unmet medical need. However, as a clinical-stage entity, it faces substantial risks associated with drug development, regulatory approval, and competition. The company's success hinges on positive clinical trial outcomes and its ability to secure ongoing financing.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., S-1, 10-K, 10-Q)
- Financial Data Providers (e.g., Bloomberg, Refinitiv, FactSet)
- Industry Research Reports
- Company Investor Relations Website
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy is based on available public information and may not be exhaustive or up-to-date. Investment decisions should be made in consultation with a qualified financial advisor. The AI-based rating is an automated assessment and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Contineum Therapeutics, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-04-05 | President, CEO & Director Mr. Carmine N. Stengone MBA, MS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.contineum-tx.com |
Full time employees 41 | Website https://www.contineum-tx.com | ||
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.